Heart Month

 

This American Heart Month, Cleerly Health wants to provide education around precision heart disease detection technology that can help you #KnowYourHeartStory. Heart disease remains the #1 public health epidemic in the world, causing nearly 17.9 million deaths annually.1 This is why we believe it is critical that every person understand their unique heart disease risk and have access to precision heart care that accurately measures their heart health.

70%
of patients who suffer a heart attack are considered “low risk” by traditional tests .2

Do You #KnowYourHeartStory?

Play our quick quiz below to test your heart health knowledge.

 

Heart Disease is often referred to as a “silent killer:” 50% of individuals who experience a heart attack will do so without having any previous symptoms.3 Heart Disease also causes the deaths of nearly 700,000 Americans annually.4 Despite how common heart disease is, and how high the stakes can be when it is missed, current diagnostic methods, such as cholesterol or blood pressure, misidentify 70% of all patients who will suffer a heart attack as low-risk.5 Throughout the month of February, we will share essential facts that can help you take ownership of your heart health. Learn what puts you at higher risk and what tools are available to help you to transform your health, no matter your background, family history or lifestyle.

Sign up to receive Cleerly communications about the science of heart disease prevention.

 

Subscribe
 

HEART MONTH RESOURCES

Learn what to expect with a CCTA heart scan
Read our Blog
what-to-expect-cleerly-ccta-scan---featured-image
In 1964, U.S. President Lyndon B. Johnson declared the first #heartmonth. Ever since, U.S. presidents have continued the tradition.
View This Year's Proclamation
In 1964, U.S. President Lyndon B. Johnson declared the first #heartmonth.
AARP interviews CEO and founder of Cleerly Dr. James Min about fighting heart disease in America
Read Now
AARP American Heart Month Image
#GoRedforWomen | Join Cleerly as we encourage women to take charge of their heart health.
Go Red for Women
Heart Month 2023 - Heart Collage
Our founder and CEO Dr. James Min  spoke with CNBC how AI is changing heart disease detection
Learn How
Cleerly CEO and Founder Dr. James Min on CNBC
Cleerly Scan Analysis with Heartbeat Health
Request an Appointment
Heartbeat Health x Cleerly
Envisioning a World Without Heart Attacks
Read More
generational-heart-disease-grandmother-daughter

 

ABOUT CLEERLY

Cleerly is a healthcare technology company dedicated to the mission of creating a world without heart attacks. Our software analyzes CT scans of a person’s heart and uses artificial intelligence (AI) to identify plaque build-up in the coronary arteries, which can be used to help identify a person’s risk of heart attack. Our technology is based on over 40,000 patient heart scans and six multi-center clinical trials. Visualize the changes in your heart with Cleerly’s compare feature, which allows you to see images of your heart from different time periods side-by-side and evaluate your progress


References:
1 Cardiovascular diseases. World Health Organization.
2 A Special Workforce Edition of the National Hospital Flash Report. Kaufman Hall. May 11, 2022.
3 Benjamin EJ et al. Circulation 2019.
4 Leading Causes of Death. National Center for Health Statistics. Last reviewed Jan.13, 2022.
5 Preventing Myocardial Infarction in the Young Adult in the First Place. JACC. May 2003.

 

Connect With Us to Learn More

Subscribe to receive Cleerly news, product information, and upcoming events.

Subscribe
Patents

Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.

Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 11,922,627, 11,948,301, 12,023,190, 11,861,833, 11,967,078, 11,832,982, 11,690,586, 11,779,292, 11,730,437, 11,672,497, 11,737,718, 11,751,826, 11,660,058, 11,896,415, 11,751,830, 11,751,829, 11,302,001, 11,308,617, 11,238,587, 11,302,002, 11,321,840, 11,341,644, 11,244,451, 11,288,799, 11,276,170, 11,210,786, 11,232,564, 11,367,190, 11,315,247, 11,969,280, 11,094,060, 11,120,550, 11,120,549, 11,132,796, 11,094,061, 11,113,811, 11,501,436, 11,751,831, 11,642,092, 11,759,161, 11,317,883, 11,350,899, 11,766,230, 11,766,229, and 10,813,612, as well as other patents that are pending.

For additional information, please contact legal@cleerlyhealth.com.

Solutions
About

© 2025 Cleerly, Inc.